Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Inc (SPRO) is a clinical-stage biopharmaceutical company that develops and commercializes novel treatments for multidrug-resistant bacterial infections and rare diseases. The company's lead product candidate, tebipenem HBr (SPR994), is a carbapenem-class antibiotic being developed for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis caused by gram-negative bacteria. SPRO is also developing SPR206, a next-generation IV-administered polymyxin product candidate, for the treatment of gram-negative infections, including carbapenem-resistant Enterobacteriaceae. The company's rare disease portfolio includes SPR720, an oral therapy for the treatment of rare, orphan diseases caused by underlying metabolic deficiencies.